Navigation Links
New Report Illuminates Ampligen's Unique Mechanism of Action

rtfolios of expiring patents and the corresponding potential for global generic competition. However, specific TLR promoters, such as Ampligen(R), may have the potential to increase the efficacy of a broadly diverse set of previously licensed biological products, thus effectively extending their useful commercial life cycles." Hemispherx has a set of patent applications pending worldwide related to safely enhancing the therapeutic responses of biological products.

About Hemispherx Biopharma

Hemispherx Biopharma, Inc. is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx's flagship products include Alferon N Injection(R) and the experimental therapeutics Ampligen(R) and Oragens(R). Alferon N Injection(R) is approved for a category of STD infection, and Ampligen(R) and Oragens(R) represent experimental RNA nucleic acids being developed for globally important viral diseases and disorders of the immune system. Hemispherx's platform technology includes large and small agent components for potential treatment of various severely debilitating and life threatening diseases. Hemispherx has in excess of 100 patents comprising its core intellectual property estate, a fully commercialized product (Alferon N Injection(R)) and GMP certified manufacturing facilities for its novel pharma products. For more information please visit www.hemispherx.net

Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risk of competition, changing market conditions, change in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Any specifically referenced investigat
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
9. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
10. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
11. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New Report Illuminates Ampligen Unique Mechanism Action
(Date:5/20/2013)... ATLANTA , May 20, 2013  Atlantic ... developed and is commercializing a unique technology to ... founder and President, Anthony Soscia ... the Atlanta Business Chronicle ,s Health-Care Heroes ... Atlanta Business Chronicle to honor individuals and ...
(Date:5/20/2013)... May 20, 2013 Enrollment of patients with ... 2b dose-finding clinical trial of product candidate NewMet ... treatment for Type 2 diabetes. Elcelyx expects to complete ... in June. Results of the trial,s primary endpoint of ... summer, and the read-out for long-term glucose lowering and ...
(Date:5/20/2013)... Md. , May 20, 2013  Neuralstem, Inc. ... Feldman , MD, PhD, principal investigator, presented updated ... stem cell (NSI-566) trial in the treatment of amyotrophic ... ,s disease) at the neuro diabetes special medical symposium ... In a talk called "Recent Therapeutic Advances in Stem ...
Breaking Medicine Technology:Atlantic Pharmaceuticals President Named Health Care Hero Finalist in Atlanta Business Chronicle for Drug Abuse Deterrent Technology 2Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 2Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 3Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 4Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 2Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 3Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 4
(Date:5/20/2013)... (PRWEB) May 20, 2013 According to a ... Warnings at Indoor Tanning Salons,” tanning salons in ... The Food and Drug Administration wants to see cancer warnings ... a minimum age floor of eighteen for the use of ... concerns about melanoma, which has become increasingly common over the ...
(Date:5/20/2013)... According to a June 2009 Bloomberg article, ... amount to approximately $3.6 billion dollars per year (i). ... estimated that there 15 million incidents of medical harm ... everyone who receives any form of medical treatment should ... Merriam-Webster defines malpractice as “a dereliction of professional duty ...
(Date:5/20/2013)... Osborn’s Brain: Imaging, Pathology, and ... Osborn’s 1993 award winning book Diagnostic Neuroradiology (a.k.a. “The ... neuroradiology texts. , In this highly anticipated 1,300-page ... complex topics visually appealing and easy to understand. It ... with spectacular pathology examples, relevant anatomy, and the most ...
(Date:5/20/2013)... Galveston researchers have been awarded a five-year, $1.8 million ... Stroke to apply the techniques of gene therapy to ... that arises from a malfunction in the nervous system. ... millions of Americans, manifesting itself in a variety of ... intense discomfort in response to a light touch, for ...
(Date:5/20/2013)... 20, 2013 Horizon NJ Health, New ... announced that it has earned a Commendable Accreditation ... Horizon NJ Health is a wholly owned subsidiary of ... , NCQA Health Plan Accreditation is a nationally recognized ... that health plans provide to their members. Health Plan ...
Breaking Medicine News(10 mins):Health News:Tanning - FDA Wants Tanning Salons to Post Cancer Warning Signs 2Health News:Law Firm Releases New Informational Graphic on the Basics of Understanding Medical Malpractice Cases 2Health News:Osborn’s Brain from Amirsys Publishing Receives Doody’s Top Honors 2Health News:Pain, pain, go away 2Health News:Pain, pain, go away 3Health News:Horizon NJ Health Awarded Commendable Accreditation by NCQA 2Health News:Horizon NJ Health Awarded Commendable Accreditation by NCQA 3
... HIV positive girls will participate ,A beauty contest with ... 2005, which is the World AIDS Day, in which only ... ‘Miss Positive-2005’. The object of the contest is to change ... and also help HIV infected people lead a normal life. ...
... to two genes, both variant forms of a gene called ... in the smoking addiction.// The protein product of these genes ... the body. ,The two identified gene forms are ... metabolism of nicotine, more specifically found to account for slow ...
... heart failure patients in United States have better short-term ... over time.// ,Their study findings appear in the ... ,Heart failure is the most common cause of hospitalization ... ,The authors compared process of care and 30-day ...
... effective treatment option for patients with liver cancer. A ... to treat a patient who harbors a liver tumor ... surgical options are currently available for this group of ... the researchers who have now suggested a novel plan ...
... has found that besides being really harsh on the ears, ... Writing in the latest issue of the European Heart Journal ... mean an increased risk of heart attack. ,Researchers ... study between 1998 and 2001 in 32 hospitals in Berlin. ...
... (QBI) have now found a process that could lead ... and acquired brain injury. ,The research focuses on ... memory function and where the brain's ability to regenerate ... ,The study by Dr Natalie Bull and Professor ...
Cached Medicine News:Health News:Tendency To Smoke and Get Addicted Could Run In Families! 2Health News:Disparity In Survival Rates In US and Canadian heart Patients 2Health News:Novel Treatment Found To Prolong Survival Of Liver Cancer Patients 2Health News:Irritating Noise Increases Risk Of Heart Attacks 2Health News:Research Targets treatment for dementia and brain injuries 2
... contact lens cleaning solution is ... and professionally proven cleaner. A ... resulting in a very effective ... cosmetic residue, salts, mucous and ...
Round knurled handle. Overall length 130 mm....
Alvis foreign body spud 4 3/4 inches, oval curette 1 x 3 mm with fine point....
Foreign body spud angled, lightly rounded tip....
Medicine Products: